High-throughput Microneutralization Method for Feline Coronavirus
The Celigo Image Cytometer reduces assay time while providing richer, quantitative readouts to accelerate assessment of vaccine and antiviral compound candidates.
Improving the Gene Therapy Development Process using Image Cytometry
Many factors and considerations must be optimized to develop the appropriate cell-based assays for gene therapy development.
Webinar on Demand: Automated High-Throughput Analysis for Viral Infection Assays
Available on demand. In this informational webinar, Dr. Dmitry Kuksin, Nexcelom Senior Scientist, examines specific virology related assays such as plaque and foci formation, as well as antibody neutralization.
Webinar on Demand: Role of Aneuploidy and DNA Damage in the Onset of Human Solid Tumors – Lessons from Mouse Models of Chromosome Losses
Available on demand. During this webinar, Dr. Thomas will share his research in cancer biology related to DNA damage in the onset of solid tumors.
Webinar On-Demand: Cell Therapy Development for Solid Tumors
In this webinar, we highlight a variety of assays to support the development of cell therapies for solid tumors.
Improving the viral plaque assay speed, sensitivity and robustness using imaging cytometry
Improved fluorescent plaque assay method using fluorescently-labeled antibodies and the use of the Celigo image cytometer.
22nd Annual Merck Technology Symposium
Come visit us at booth #413 Merck Technology Symposium 2018 September 5-6, 2018 Ocean Place Resort Long Branch, NJ Posters being presented: High-throughput foci counting of viral titer and antibody neutralization assays using the Celigo Image Cytometer for developing a novel cross-reactive influenza vaccine Long-term time-course monitoring of NK cell-mediated ADCC using the Celigo Image Cytometer A high-throughput 3D tumor spheroid screening method for drug discovery using imaging cytometry
Celigo evaluates a plant extract for glioblastomoa multiforme treatment
At the Canary Center at Stanford for Early Cancer Detection, investigators studied how AshwaMAX (a steroidal lactone from a winter cherry plant, Withania somnifera, extract) might work as an oral treatment for those with the highly aggressive cancer glioblastoma multiforme (GBM). A heterogeneous disease, non-specific therapies for GBM have proven largely ineffective. Two patient-derived GBM lines (GBM2, GBM39) and one GBM cell line were cultured to create neurospheres that were then exposed to various concentrations of AshwaMAX. Celigo measured cell proliferation and cell death via Trypan Blue staining. AshwaMAX inhibited the neurospheres at nanomolar concentrations. After additional work in vivo, [...]
Cellometer investigates new treatment paradigm for advanced endometrial cancer
University of North Carolina researchers investigated different techniques for inhibiting the catalytic activity of protein hTERT – a marker of advanced stage endometrial cancer. Endometrial cancer cell lines ECC-1 and Ishikawa were exposed to either siRNA or a small molecule pharmacological inhibitor BIBR1532, in addition to the drug paclitaxel, to see whether inhibiting hTERT provided additional efficacy against these cancer cells. The Cellometer, in combination with propidium iodide and Annexin-V FITC, calculated apoptosis in the various treatment conditions. The hTERT inhibition plus paclitaxel did prove synergistic, reducing cell growth and invasion more than paclitaxel alone. Furthermore, BIBR1532 antagonized cell invasion [...]
Investigation of IAPP Role in Increasing ROS Production and Apoptosis in p53-deficient Tumor Cells using Celigo Imaging Cytometer
The entire family of tumor protein p53 (TP53) enhances functions such as apoptosis and autophagy in normal cellular functioning. TP53 is a tumor repressor gene that is often inactivated in human cancers. Reactivating p53 has proven difficult to achieve therapeutically, however. Researchers at MD Anderson Cancer Center are investigating other members of the p53 pathway in order to elucidate new therapeutic options to suppress p53-deficient tumor growth. ΔN isoforms of two members of the p53 family, p63 and p73, are usually overexpressed in cancers and these isoforms (which lack the acidic transactivation domain) act on p53 in a dominant-negative fashion, [...]